Our history
Since its creation ten years ago, Cemag Care has been working to improve women’s health, autonomy and quality of life by addressing medical needs that have long been overlooked or insufficiently addressed.
From the origins to the creation of Cemag Care
Cemag was founded in 2016, initially as Cemag Consulting, driven by a founding conviction:
women’s health deserves specific, practical and scientifically grounded responses.
Conceived as a space for reflection and expertise, this first structure made it possible to identify unmet medical needs, as well as persistent barriers in women’s healthcare pathways — whether medical, regulatory or societal.
Attentive to societal developments and to health issues that remain insufficiently addressed, André Ulmann initiated this approach to support health projects dedicated to women, drawing on strong scientific, medical and regulatory expertise.
In 2018, this approach naturally evolved into the creation of Cemag Care, an independent pharmaceutical company dedicated to women’s health.
This transition marked a shift from consultancy to action, with a clear ambition: to rethink women’s healthcare pathways and develop rigorous, meaningful and accessible solutions.
André Ulmann
Founder of Cemag Care
A trained physician, André Ulmann began his career in a hospital setting before joining the pharmaceutical industry. He was entrusted with a project that would have a lasting impact on his professional path: the development of mifepristone (RU-486), the first medication enabling medical abortion.
This work required confronting significant resistance, including political pressure, medical opposition and deep-rooted societal taboos. To safeguard access and prevent setbacks, he initiated large-scale clinical studies and committed over the long term to ensuring that science prevailed over ideology.
Confronted with the limitations of large pharmaceutical groups, he subsequently founded HRA Pharma, an independent pharmaceutical company dedicated to developing practical solutions in reproductive health, including emergency contraception (the “morning-after pill”). By making it available without prescription in more than 70 countries, André Ulmann and his teams helped transform the lives of millions of women worldwide.
Throughout his career, André Ulmann has consistently defended a clear vision: placing pharmaceutical innovation at the service of women’s autonomy and everyday health.
Cemag Care is part of this continuity — an independent, committed pharmaceutical company, ready to address complex and often overlooked women’s health issues.
A key milestone:
the arrival of Manon Exposito in 2019
- structuring Cemag Care’s regulatory framework,
- building the pharmaceutical establishment,
- and securing the authorisations required for its launch and continued development.
Her expertise helped lay the foundations of a rigorous pharmaceutical company, fully compliant with regulatory requirements, while remaining agile and independent.
Manon Exposito,
Chief Executive Officer
She joined Cemag Care at its creation in 2019, contributing to the establishment of the company, the structuring of its regulatory and pharmaceutical framework, and the development of its scientific projects.
Her professional background is characterised by :
- strong expertise in pharmacovigilance and regulatory affairs,
- a long-standing commitment to reproductive health,
- active involvement in the non-profit sector, including field-based work alongside associations and NGOs.